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ABSTRACT
To decrease the incidence of graft-versus-host disease (GVHD) observed after nonmyeloablative
stem cell transplantation (NMSCT), we studied the feasibility of CD8-depleted or CD34-selected
NMSCT followed by CD8-depleted preemptive donor lymphocyte infusion (DLI) given in incre-
mental doses on days 40 and 80. Fourteen patients with high-risk malignancies and an HLA-iden-
tical sibling (n 5 8) or alternative donor (n 5 6) but ineligible for a conventional transplant were
included. Nonmyeloablative conditioning regimen consisted in 2 Gy total body irradiation (TBI)
alone, 2 Gy TBI and fludarabine (previously untreated patients) or cyclophosphamide and flu-
darabine (patients who had previously received $12 Gy TBI). Patients 1–4 (controls) received un-
manipulated peripheral blood stem cells (PBSC) and DLI and patients 5–14 CD8-depleted or CD34-
selected PBSC followed by CD8-depleted DLI. Post-transplant immunosuppression was carried out
with cyclosporine A (CsA) and mycophenolate mofetil (MMF). Initial engraftment was seen in all
patients, but 1 patient (7%) later rejected her graft. The actuarial 180-day incidence of grades II–IV
acute GVHD was 75% for patients 1–4 versus 0% for patients 5–14 (p 5 0.0019). Five of 14 patients
were in complete remission (CR) 180 days after the transplant and 6/14 had partial responses. The
1-year survival rate was 69%, and nonrelapse and relapse mortality rates were 16 and 18%, re-
spectively. We conclude that CD8-depleted or CD34-selected NMSCT followed by CD8-depleted
DLI is feasible and considerably decreases the incidence of acute GVHD while preserving engraft-
ment and apparently also the graft-versus-leukemia (GVL) effect. Further studies are needed to
confirm this encouraging preliminary report.
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INTRODUCTION
ALLOGENEIC HEMATOPOIETIC STEM CELL (HSC) trans-plants are classically performed after myeloablative
regimens consisting of high-dose chemotherapy with or
without total body irradiation (TBI) (1,2). The aims of
this conditioning are to eliminate host (1) hematopoiesis
to “make space” for donor HSC; (2) immune system to
prevent rejection; and (3) cancer or leukemic cells (3).
However, it has been recently demonstrated that the graft
itself, most likely through subclinical graft-versus-host
disease (GVHD) reactions, is capable to create these mar-
row spaces without chemotherapy or bone marrow irra-
diation (4). In addition, tumor cells resistant to standard
doses of chemotherapy are unlikely to be completely
eliminated by tolerable higher-intensity doses of chemo-
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radiotherapy alone (5). Moreover, donor alloreactivity
against tumor cells has been recognized as a major fac-
tor in the success of HSC transplantation (6–10). This
graft-versus-leukemia (GVL) effect may be so potent that
leukemia relapses after standard allogeneic transplanta-
tion can be effectively [70% long-term complete remis-
sion (CR) in chronic myeloid leukemia (CML)] treated
with donor lymphocyte infusions (DLI) (10–17). Taken
together, these findings suggested that the potential for
cure after allogeneic HSC transplantation could be ob-
tained by induction of host-versus-graft tolerance with
low-dose highly immunosuppressive regimens, allowing
in a second step the implantation of donor T and natural
killer (NK) (18,19) cells (DLI) to eradicate host tumor
cells (3,5,20–32).
The Seattle team has recently proposed an original ap-
proach to nonmyeloablative stem cell transplantation (NM-
SCT) with a conditioning regimen based on single-dose (2
Gy) TBI followed by post-transplant immunosuppression
with cyclosporine A (CsA) and mycophenolate mofetil
(MMF) (3,33,34). They observed a powerful GVL effect
but also a significant incidence of GVHD (33). Recently,
we have reported a prospective study of transplantation of
CD34-selected allogeneic peripheral blood stem cells
(PBSC) after myeloablative conditioning, followed by pre-
emptive CD8-depleted DLI (35). Compared to unmanip-
ulated marrow transplantation, this approach significantly
decreased the incidence of acute and extensive chronic
GVHD without compromising the GVL effect. Therefore,
we undertook to investigate the feasibility of applying such
a strategy of CD8-depletion or CD34-selection of the graft
followed by pre-emptive CD8-depleted DLI in the context
of NMSCT after a conditioning and immunosuppression
regimen based on the Seattle approach.
PATIENTS AND METHODS
Patient eligibility
Patients with hematologic malignancies were eligible
for this program if they were deemed poor candidates for
conventional myeloablative therapy because they were
older than 55 years (n 5 4), had concurrent medical con-
ditions (n 5 0), had failed a previous autograft (n 5 4),
or for a combination of these factors (n 5 3). Patients
with metastatic renal cell carcinoma refractory to inter-
feron-a were also eligible (n 5 3). Written informed con-
sent was obtained from patients and donors and our in-
stitution’s Ethical Committee approved the protocol.
Patients and donors
Fourteen patients with malignancies, 12 males and 2
females, aged 22–65 (median 58) years were included.
Their clinical characteristics are summarized in Table 1.
The number of previous lines of therapy ranged from 1
to 6. Eight patients had undergone a previous autotrans-
plant with 6/8 failures. Only those with CML or renal
cell carcinoma (RCC) did not receive a previous auto-
graft. Eight patients had HLA-identical sibling and 6 al-
ternative donors. Conditioning (Table 2) consisted of 2
Gy of single-dose TBI on day 0 (n 5 6). For patients not
heavily pretreated or unrelated transplants, TBI was com-
bined with 30 mg/m2 per day fludarabine for 3 days (n 5
5). The first patient was an exception to this rule because
the high rejection rate in CML patients with the original
Seattle protocol was not yet published. Finally, 3 patients
received a combination of fludarabine and cyclophos-
phamide 1 g/m2 per day for 3 days (Fluda-Cy) because
they had previously received 12 Gy TBI as conditioning
regimen for an autotransplant (Table 1). Post-transplant
immunosuppression was carried out orally with CsA (6
mg/kg b.i.d. from day 21 to day 120 or longer in case
of alternative donor or chronic GVHD) and MMF (15
mg/kg b.i.d. from day 21 to day 28).
Clinical management
The trigger values for red blood cell (RBC) and platelet
transfusion were 8.0 g/dl and 15 3 109/L, respectively.
Granulocyte colony-stimulating factor (G-CSF) (5
mg/kg/d) was administered when the granulocyte count
was below 1.0 3 109/L. The diagnosis and grading of
acute and chronic GVHD was established as previously
reported (36,37). Disease evaluation were routinely car-
ried out on days 40, 100, 180, and 365. Polymerase chain
reaction (PCR) for cytomegalovirus (CMV) was per-
formed weekly until day 100 and every 2–4 weeks there-
after. Patients with a positive PCR received preemptive
ganciclovir for a minimum of 4 weeks and generally up
to day 100.
Stem cell mobilization, collection, and selection
Donors received human G-CSF (Neupogen®, kindly
provided by Amgen, Brussels, Belgium) at 10 mg/kg from
day 25 through day 21 before transplant. Collection of
PBSC was carried out on days 21 and 0, using a con-
tinuous flow blood cell separator (CS30001, Baxter-Fen-
wall Laboratories, Deerfield, IL, or Cobe Spectra, Lake-
wood, CO). The volume of blood processed was 12–16
liters. The PBSC from the first day of harvest were stored
overnight in the patient’s own plasma. Patients 1–4 re-
ceived unmanipulated PBSC. In patients 5–11, PBSC
were CD8-depleted and in patients 12–14 PBSC were
CD34-selected (Fig. 1). Immediately after the second har-
vest, PBSC from the first and second harvests were
pooled. CD8 depletion as well as CD341 cell selection



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































arator (Nexell International, Wemmel, Belgium), ac-
cording to the manufacturer’s recommendations.
Donor lymphocyte infusions
Around day 40 post-transplantation, donors underwent
12- to 16-liter leukophereses on 2 consecutive days to col-
lect lymphocytes. The collection from the first day of har-
vest was stored overnight in the patient’s own plasma and
pooled with the second harvest. Patients 1–4 (unmanipu-
lated PBSC) were assigned to receive unmanipulated DLI
(1 3 107 and 2 3 107 CD31 cells/kg recipient around
days 40 and 80, respectively) whereas patients 5–14 (ma-
nipulated PBSC) were assigned to receive CD8-depleted
DLI (1 3 107 and 5 (2 in mismatched transplants) 3 107
CD31 cells/kg recipient around days 40 and 80, respec-
tively) (Fig. 1). CD8-depletion of DLI was carried out
with Nexell Isolex 300i© as previously reported. The first
DLI was infused fresh whereas the following ones were
cryopreserved and thawed. DLI were not to be given in
case of an antecedent grade III–IV acute GVHD or active
GVHD at time of scheduled infusions nor in recipients of
unrelated transplants. Patients with mixed chimerism on
day 100 received a third DLI around day 120.
Laboratory analyses
Aliquots of the pooled PBSC as well as the CD8-de-
pleted or CD34-selected fractions were incubated with
phycoerythrin (PE)-conjugated anti-CD34, CD3, CD4,
CD8, and CD56 monoclonal antibodies (HPCA2; Bec-
ton-Dickinson, Palo-Alto, CA) for 20 min at 20°C,
washed, and fixed. A total of 1 3 105 cells/condition was
analyzed using a FACS-scan analyzer (Becton-Dickin-
son). The percentage of CD341 cells was defined with
dot plot analysis using the whole nucleated cell popula-
tion. The percentage of positive cells in the isotype con-
trol was subtracted from the CD341 percentage to give
the final percentage of CD341 cells. Data acquisition was
performed with the Cellquest software (Becton-Dickin-
son). Donor lymphocytes (before and after CD8 deple-
tion) are well as patient peripheral white blood cells (on
days 28, 42, 60, 80, 100, 120, 180, and 365) were simi-
larly examined using double labeling with fluorescein
isothiocyanate (FITC)- and PE-conjugated antibodies af-
ter treatment with a lysing solution.
Chimerism among peripheral blood white blood cells
(WBC), T cells, and myeloid cells as well as in unfrac-
tionated marrow was assessed at days 28, 42, 60, 80, 100,
120, 180, and 365 after HCT using fluorescence in situ hy-
bridization (FISH) to detect X and Y chromosomes for re-
cipients of sex-mismatched transplants and PCR-based
analysis of polymorphic minisatellite or microsatellite re-
gions for recipients of sex-matched transplants (38). CD3
(T cells) and CD13 (myeloid cells) selection was carried
out with a FACStar Plus sorter (Becton-Dickinson). Mixed
chimerism (MC) was defined as between 1% and 94%
donor cells and full chimerism (FC) as $95% donor cells.
Statistical analyses
The probability of GVHD, transplant-related mortality
(TRM), and survival were studied by life-table analyses,
and Wilcoxon rank tests were used for comparisons be-
tween groups. Statistical analyses were carried out with
Graphpad Prism (Graphpad Software, San Diego, CA).
RESULTS
Collection of PBSC, CD8 depletion, 
and CD34 selection
A median of 8.0 (2.6–15.3) 3 106 CD341 cells/kg,
328 (168–753) 3 106 CD31 cells/kg, 207 (92–424) 3
NMSCT WITH CD8-DEPLETED OR CD34-SELECTED PBSC
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FIG. 1. Schedule of the study. MMF, mycophenolate mofetil.
106 CD41 cells/kg, and 108 (62–496) 3 106 CD81
cells/kg were collected (Table 2). After CD8 depletion,
a median of 4.54 (2.65–10.43) 3 106 CD341 cells/kg,
136 (63–249) 3 106 CD31 cells/kg, 121 (55–185) 3 106
CD41 cells/kg, and 4 (1–22) 3 106 CD81 cells/kg were
infused (Table 2). The procedure reduced the number of
CD31, CD41, and CD81 cells infused by 0.38, 0.22, and
1.7 log, respectively. After CD34 selection, a median of
5.71 (1.83–7.28) 3 106 CD341 cells/kg, 0.08
(0.08–0.11) 3 106 CD31 cells/kg, 0.04 (0.03–0.06) 3
106 CD41 cells/kg, and 0.05 (0.03–0.06) 3 106 CD81
cells/kg were infused (Table 2). The procedure reduced
the number of CD31, CD41, and CD81 cells infused by
3.6, 3.7, and 3.6 log, respectively.
Toxicities and engraftment
None of the 14 patients developed grade 2 or higher
regimen-related toxicities (39). Initial engraftment was
observed in 100% of the patients, and nonfatal graft re-
jection occurred only in 1 CML patient (patient #1,
whose conditioning did not include fludarabine). The
actuarial 180-day incidence of graft rejection was 9%.
The neutrophil nadir occurred on day 7 and was 0.72
(0.09 to 2.33) 3 109/L (Fig. 2A). Ten out of 14 patients
(75%) received a median of 4 (0–8) doses of G-CSF
for treatment of neutropenia (Fig. 2C). The median
platelet nadir was 88 (8–191) 3 109/L (Fig. 2B), and
only 3/14 patients (21%) required 1 single (n 5 2) or
6 (n 5 1) platelet transfusions (Fig. 2C). Finally, the
median hemoglobin (Hb) nadir was 10.2 (7.3–11.8)
g/dL and 4 patients (29%) required RBC transfusions
(1, 2, 3, and 9 units, respectively) during the first month
after HSCT (Fig. 2C).
Infections, CMV reactivation, and hospitalization
Six patients (that received only 2 Gy TBI as condi-
tioning regimen) were eligible for outpatient transplan-
tation. Four of the 6 patients did not require hospitaliza-
tion within 100 days of HSCT. The other patients were
hospitalized before transplant for administration of flu-
darabine with (n 5 3) or without (n 5 5) cyclophos-
phamide. They were discharged on day 1 (range 0–9) and
6 of them were rehospitalized within 100 days of HSCT
for a median duration of 7 (range 0–35) days.
Forty-three percent of the patients experienced bacte-
rial infections within 100 days of transplant that were
successfully managed by antibiotics except in patient 10
who died of pseudomonas septic shock and lung as-
pergillosis on day 51. In addition, 1 patient died of 
(presumably viral) encephalitis on day 186. PCR CMV
reactivation was detected in 8 of 11 (73%) CMV-seropos-
itive patients and was successfully managed by preemp-
tive ganciclovir in all of them (Table 3).
Donor lymphocyte infusions and chimerism
Four patients (patients 2 and 3, who had active GVHD
at that time, as well as patients 10 and 11, who under-
went unrelated transplants) did not received preemptive
DLI (Table 3). On the other hand, 3 patients received ad-
ditional DLI for poor chimerism and/or persistence of the
underlying disease. DLI were well tolerated and no pa-




FIG. 2. Evolution of neutrophil (A) and platelet (B) counts
in the immediate post-transplant period. (C) Number of RBC




















































































































































































































































































































































































































































































































































































































































































































































































The evolution of chimerism is shown in Fig. 3. Total
white blood cell, CD31 cell, CD131 cell, and bone mar-
row (BM) chimerisms were 83% (50–97), 90% (30–98),
95% (50–98), and 90% (50–97), respectively, on day 28;
90% (48–100), 94% (37–100), 95% (71–100), and 90%
(7–99), respectively on day 100; and 95% (9–100), 78%
(18–98), 98% (3–100), and 97% (60–100), respectively,
on day 180. The lowest figures were obtained in patient
1, who rejected her graft after day 100. Two of 3 patients
who were full donor chimera (FC) before DLI remained
FC after DLI (the third died before DLI). In addition,
CD8-depleted DLI converted MC to FC in 5/9 evaluable
patients. Thus, FC was achieved in 9/12 evaluable pa-
tients. For CD8-depleted or CD34-selected transplant re-
cipients, WBC and BM chimerisms were 83% (64–97)
and 89% (70–94), respectively, on day 28; 90% (73–100)
and 90% (74–90), respectively, on day 100; and 95%
(73–96) and 95% (60–100), respectively, on day 180.
Acute and chronic GVHD
The actuarial 180-day incidence of grade II–IV acute
GVHD was 23% (Fig. 4). Three out of 4 patients who
received unmanipulated PBSC and DLI (patients 1–4)
versus 0/10 patients who received CD8-depleted or
CD34-selected PBSC and CD8-depleted DLI (patients
BARON ET AL.
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FIG. 3. Evolution of WBC chimerism on days 28 (black bars), 100 (white bars), and 180 (gray bars) after transplantation.
FIG. 4. (A) Actuarial 180-day incidence of grades II–IV acute GVHD. (B) Actuarial 1-year probability of extensive chronic
GVHD.
5–14) experienced grade $ II acute GVHD (Table 3).
The actuarial 180-day incidence of grade II–IV acute
GVHD was 75% for patients 1–4 versus 0% for patients
5–12 (p 5 0.0019) (Fig. 4). The actuarial 1-year proba-
bilities of chronic GVHD and extensive chronic GVHD
were 68 and 53%, respectively (Fig. 4). For patients 5–14,
the figures were 57% and 43%, respectively. For patients
1–4, the figures were 100% and 100%, respectively.
Immune recovery
CD41 T cells remained greater than 200/ml in 7/13
evaluable patients (Fig. 5). The CD81 cell recovery was
fast and 9/11 evaluable patients had more than 200 CD81
T cells/ml on day 40. Patients conditioned with Fluda-Cy
had slower CD41 and CD81 T cell recovery compared
to other patients (Fig. 5A,B). On day 40, the median num-
ber of CD41 T cells/ml was 94 (51–127) for Fluda-Cy
recipients versus 315 (156–570) for other patients (p 5
0.0160). For CD81 T cells, the figures were 104 (76–283)
and 369 (161–676), respectively (p 5 0.07). On the other
hand, PBSC manipulation apparently also impacted on
immune recovery. Patients 1–4 (unmanipulated PBSC)
had a higher CD81 cell count than patients 5–14 (Fig.
5C,D). Finally, mean CD41 and CD81 cell counts re-
mained low despite DLI for at least 180 days after CD34-
selected transplants (Fig. 5C,D).
Disease responses
Five patients were grafted for refractory or poor prog-
nosis non-Hodgkin’s lymphoma (NHL (see Fig. 6)). Four
of them were in CR 6 months after the transplant. Patient
11 who developed NHL after an autologous HSCT for
refractory Hodgkin’s disease was in CR before and re-
mained in CR .6 months after the transplant. One pa-
NMSCT WITH CD8-DEPLETED OR CD34-SELECTED PBSC
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FIG. 5. CD41 T cell (A and C) and CD81 T cell (B and D) reconstitution after transplantation. In A and B, patients receiv-
ing Fluda-Cy conditioning (broken line) and other patients (continuous line) are shown separately. In C and D, patients receiv-
ing unmanipulated PBSC (patients 1–4; continuous line and closed triangles), CD8-depleted PBSC (patients 5–11; broken line
and open triangles), or CD34-selected PBSC (patients 12–14; broken line and stars) are shown separately. The horizontal line in-
dicates the lower limit of normal values.
tient with refractory chronic lymphocytic leukemia
(CLL) showed a partial response. The two CML patients
achieved hematologic remission and major cytogenetic
responses (11 and 14% Ph1 BM cells on FISH analysis).
Unfortunately, the first patient rejected her graft while
developing blast crisis on day 141. The second one is
currently treated with DLI after cyclosporine discontin-
uation. Three patients were treated for RCC. The first one
(patient 2) achieved partial response on day 180 that fur-
ther improved on day 365. The second one (patient 7 who
had a 15-cm lung metastasis) died of disease progression
on day 24. The third one is not yet evaluated for response.
The 2 patients with acute leukemia in CR remained in
CR 511 and 1801 days after the transplant. Finally, a
patient with Hodgkin’s disease (HD) in CR after autolo-
gous HSCT and mediastinal radiotherapy remains in CR
more than 1 year after the NMSCT. The 1-year proba-
bility of relapse mortality was 18%.
Transplant-related mortality and survival
After a median follow-up of 230 (44-561) days, 10 of
14 patients (71%) were alive. The actuarial 1-year prob-
ability of survival was 69% (Fig. 7A). Two patients died
of progressive disease, 1 of septic shock, and 1 of en-
cephalitis. The actuarial 180-day and 1-year probabilities
of transplant-related mortality (TRM) were 8 and 16%,
respectively (Fig. 7B).
DISCUSSION
NMSCT is based on a two-step approach: first, induc-
tion of mixed chimerism and then, in a second step, erad-
ication of malignant cells by the GVL effect (5,9). The
Seattle group has developed a very-low-intensity condi-
tioning regimen with only 2 Gy TBI and post-grafting
immunosuppression with CsA and MMF (33,34). This
approach allowed the transplant procedure to be per-
formed in an outpatient setting in about 50% of the pa-
tients and clearly induced a strong GVL effect with a low
TRM (34). However, a high rate of graft rejection was
observed in patients who had not previously received in-
tensive chemotherapy.
In our study, initial engraftment was seen in all patients.
Chimerism analysis on day 42 in the first patient included
[a CML patient in first chronic phase (CP)] evidenced poor
chimerism (30% T cell and 50% myeloid as well as BM
chimerism). She subsequently rejected her graft around
day 100. This observation, as well as the report of similar
cases by the Seattle team led us to add fludarabine in the
conditioning regimen of patients not heavily pretreated,
such as CML and RCC patients. This modified condition-
ing permitted to achieve durable engraftment in all other
patients. To avoid radiation-induced organ damage, pa-
tients who had previously received $12 Gy TBI had a non-
myeloablative conditioning regimen consisting of cy-
clophosphamide 3 g/m2 and fludarabine 90 mg/m2. This
later conditioning regimen also allowed us to conduct the
immediate post-transplant course in an outpatient setting,
although the degree of myelosuppression was higher. CD8-
depletion or CD34-selection of the graft was not associ-
ated with initial graft failure or graft rejection, even in mis-
matched or unrelated transplant recipients. In such patients,
initial as well as long-term chimerism was at least as good
as in patients receiving unmanipulated PBSC. Although it
was thought that a large dose of donor T lymphocytes (and
particularly CD81 lymphocytes) (40) was required to im-
plant an allogeneic graft in the NMSCT setting (4,41), this
study demonstrated for the first time that the absence of
CD8 lymphocytes, or even of any lymphocytes, in the graft
does not impair initial engraftment and sustained
chimerism after a very mild nonmyeloablative regimen and
post-transplant CsA and MMF.
BARON ET AL.
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FIG. 6. Evolution of disease response after transplantation.
(j ) Progression; ( ) stabilization; ( ) partial response $ 25%;
( ) partial response $ 50%; ( ) partial response $ 75%; ( u )
complete remission.
Acute and chronic GVHD remained a substantial lim-
itation of the Seattle approach: the incidence of grade II,
III, and IV acute GVHD were 33%, 13%, and 4%, re-
spectively (33), and the incidence of chronic GVHD was
74% (34). In animal models, it is now well demonstrated
that donor lymphocytes given several weeks after the
transplant in mixed chimera induce significantly less
GVHD than a similar dose of donor T cells given to-
gether with the graft (41,42), without reducing their an-
titumor efficacy (21,41). More recently, we have reported
that after a myeloablative conditioning regimen, the
transplantation of CD34-selected allogeneic PBSC fol-
lowed by pre-emptive CD8-depleted DLI significantly
decreased the incidence of acute and severe chronic
GVHD compared to transplantation of unmanipulated
bone marrow (35). Therefore, we evaluated the feasibil-
ity of transplanting T cell-depleted PBSC (by CD8-de-
pletion or by CD34-selection) followed by preemptive
CD8-depleted DLI after a mild nonmyeloablative regi-
men.
Three of the 4 patients (including 2 mismatched trans-
plants) who received unmanipulated PBSC and DLI de-
veloped grades II–IV acute GVHD and chronic GVHD.
On the other hand, none of the 10 patients who received
CD8-depleted or CD34-selected PBSC and pre-emptive
CD8-depleted DLI experienced grades II–IV acute
GVHD, although this group also included 2 mismatched
and 2 unrelated transplants. We chose to give preemp-
tive DLI under cyclosporine prophylaxis because two
previous reports have shown that this strategy maintains
the GVL effect (35,43). Moreover, in a preliminary re-
port of the French transplant group, the duration of 
cyclosporine prophylaxis after NMSCT was strongly as-
sociated with increased overall survival (44). Unfortu-
nately, despite the short follow-up of our patients, the in-
cidence of extensive chronic GVHD in CD8-depleted
transplants was still significant (43%), although lower
than that reported by the Seattle team and that observed
in our patients receiving unmanipulated PBSC and DLI
(in 3 patients).
The small number of patients included as well as their
heterogeneity does not allow an accurate estimate of the
GVL effect. However, responses were observed in both
the unmanipulated and CD8-depleted or CD34-selected
groups, suggesting that these latter approaches did not
impair the GVL effect, at least when preemptive CD8-
depleted DLI are systematically given after the PBSC
transplant.
Another approach (than CD8-depletion) to separate the
GVL effect from GVHD would be to infuse specific cy-
totoxic T cells (CTL) instead of DLI. Donor-derived CTL
have been successfully used for the treatment of CMV
infections (45) or for prevention or treatment of Epstein-
Barr virus (EBV)-associated lymphoma after allogeneic
HSCT (46). Remarkably, no significant toxicity nor
GVHD were observed with this early post-transplant cell
immunotherapy. Recently, the Leiden group reported the
achievement of CR by treatment with leukemia-reactive
CTL in a patient with accelerated phase CML refractory
to standard DLI (47,48). The infusion of donor-derived
CTL against specific antigens such as minor histocom-
patibility antigen (mHA) preferentially expressed in the
hematopoietic system (49,50), tumor-specific antigens
(51), or antigens overexpressed in tumor cells (52,53) af-
ter CD8-depleted or CD34-selected PBSC may permit the
GVL effect to be increased greatly while minimizing the
risk of GVHD.
In conclusion, our study showed that CD8-depleted
and CD34-selected PBSC can engraft after a light con-
ditioning regimen consisting of 2 Gy TBI (and fludara-
bine for previously untreated patients). The preliminary
results suggest that CD8 depletion or CD34 selection of
the graft followed by CD8-depleted DLI strongly de-
NMSCT WITH CD8-DEPLETED OR CD34-SELECTED PBSC
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FIG. 7. (A) Probability of survival. (B) Probability of trans-
plant-related mortality.
crease the incidence of acute GVHD while apparently
preserving the GVL effect. Further studies are needed to
confirm this preliminary report, to assess the impact of
our strategy on the incidence and severity of chronic
GVHD, and to investigate the infusion of specific CTL
instead of CD8-depleted DLI.
ACKNOWLEDGMENTS
Frédéric Baron is Research Assistant and Yves Beguin
Research Director of the National Fund for Scientific Re-
search (FNRS, Belgium). This work was supported by
grants from “La Fondation Bonjean- Oleffe,” “L’Asso-
ciation sportive contre le Cancer,” “Le Fonds de
Recherche Scientifique du CHU Sart-Tilman,” and the
National Fund for Scientific Research (FNRS, Belgium).
REFERENCES
1. Storb R. (1995). Bone marrow transplantation. Transplant
Proc 27:2649–2652.
2. Buckner CD, RB Epstein, RH Rudolph, RA Clift, R Storb
and ED Thomas. (2001). Allogeneic marrow engraftment
following whole body irradiation in a patient with leuke-
mia. J Hematother Stem Cell Res 10:201–208.
3. McSweeney PA and R Storb. (1999). Mixed chimerism:
preclinical studies and clinical applications. Biol Blood
Marrow Transplant 5:192–203.
4. Storb R, C Yu, T Barnett, JL Wagner, HJ Deeg, RA Nash,
HP Kiem, PA McSweeney, K Seidel, G Georges and JM
Zaucha. (1999). Stable mixed hematopoietic chimerism in
dog leukocyte antigen-identical littermate dogs given
lymph node irradiation before and pharmacologic im-
munosuppression after marrow transplantation. Blood
94:1131–1136.
5. Slavin S, A Nagler, E Naparstek, Y Kapelushnik, M Aker,
G Cividalli, G Varadi, M Kirschbaum, A Ackerstein, S
Samuel, A Amar, C Brautbar, O Ben-Tal, A Eldor and R
Or. (1998). Nonmyeloablative stem cell transplantation and
cell therapy as an alternative to conventional bone marrow
transplantation with lethal cytoreduction for the treatment
of malignant and nonmalignant hematologic diseases.
Blood 91:756–763.
6. Horowitz MM, RP Gale, PM Sondel, JM Goldman, J
Kersey, HJ Kolb, AA Rimm, O Ringden, C Rozman and
B Speck. (1990). Graft-versus-leukemia reactions after
bone marrow transplantation. Blood 75:555–562.
7. Drobyski WR. (2000). Evolving strategies to address ad-
verse transplant outcomes associated with T cell depletion.
J Hematother Stem Cell Res 9:327–337.
8. Barrett J and R Childs. (2000). The benefits of an allore-
sponse: graft-versus-tumor. J Hematother Stem Cell Res
9:347–354.
9. Morecki S and S Slavin. (2000). Toward amplification of
a graft-versus-leukemia effect while minimizing graft-ver-
sus-host disease. J Hematother Stem Cell Res 9:355–366.
10. Baron F and Y Beguin. (2000). Adoptive immunotherapy
with donor lymphocyte infusions after allogeneic HPC
transplantation. Transfusion 40:468–476.
11. Slavin S, E Naparstek, A Nagler, A Ackerstein, J Kapelush-
nik and R Or. (1995). Allogeneic cell therapy for relapsed
leukemia after bone marrow transplantation with donor pe-
ripheral blood lymphocytes. Exp Hematol 23:1553–1562.
12. Porter DL. (2001). The graft-versus-tumor potential of al-
logeneic cell therapy: an update on donor leukocyte infu-
sions and nonmyeloablative allogeneic stem cell trans-
plantation. J Hematother Stem Cell Res 10:465–480.
13. Baron F, P Frère, G Fillet and Y Beguin. (2001). Treat-
ment of leukaemia relapse after allogeneic hematopoietic
stem cell transplantation by donor lymphocyte infusion and
STI-571. Haematologica 86:993–994.
14. Mattei D, G Saglio, E Gottardi, A Gallamini, N Mordini,
and A Bacigalupo. (2001). Persisting molecular remission
ten years after donor lymphocyte infusion for hematologic
relapse in chronic myeloid leukemia. Haematologica
86:545–546.
15. Kolb HJ, A Schattenberg, JM Goldman, B Hertenstein, N
Jacobsen, W Arcese, P Ljungman, A Ferrant, L Verdonck
and D Niederwieser. (1995). Graft-versus-leukemia effect
of donor lymphocyte transfusions in marrow grafted pa-
tients. European Group for Blood and Marrow Transplan-
tation Working Party Chronic Leukemia. Blood 86:
2041–2050.
16. Collins RHJ, O Shpilberg, WR Drobyski, DL Porter, S Gi-
ralt, R Champlin, SA Goodman, SN Wolff, W Hu, C Ver-
faillie, A List, Dalton, N Ognoskie, A Chetrit, JH Antin
and J Nemunaitis. (1997). Donor leukocyte infusions in 140
patients with relapsed malignancy after allogeneic bone
marrow transplantation. J Clin Oncol 15:433–444.
17. Alyea EP. (2000). Adoptive immunotherapy: insights from
donor lymphocyte infusions. Transfusion 40:393–395.
18. Klingemann HG. (2001). Cellular therapy of cancer with
natural killer cells: will it ever work? J Hematother Stem
Cell Res 10:23–26.
19. Chiorean EG and JS Miller. (2001). The biology of natural
killer cells and implications for therapy of human disease.
J Hematother Stem Cell Res 10:451–463.
20. Baron F and Y Beguin. (2002). Nonmyeloablative allo-
geneic hematopoietic stem cell transplantation. J Hema-
tother Stem Cell Res 11:243–263.
21. Spitzer TR, S McAfee, R Sackstein, C Colby, HC Toh, P
Multani, SL Saidman, D Weymouth, F Preffer, C Poliquin,
A Foley, B Cox, DM Andrews, DH Sachs and M Sykes.
(2000). Intentional induction of mixed chimerism and
achievement of antitumor responses after nonmyeloabla-
tive conditioning therapy and HLA-matched donor bone
marrow transplantation for refractory hematologic malig-
nancies. Biol Blood Marrow Transplant 6:309–320.
22. Carella AM, R Champlin, S Slavin, PA McSweeney and
R Storb. (2000). Mini-allografts: ongoing trials in humans.
Bone Marrow Transplant 25:345–350.
23. Nagler A, S Slavin, G Varadi, E Naparstek, S Samuel and
R Or. (2000). Allogeneic peripheral blood stem cell trans-
plantation using a fludarabine-based low intensity condi-




24. Nagler A, M Aker, R Or, E Naparstek, G Varadi, C Braut-
bar and S Slavin. (2001). Low-intensity conditioning is suf-
ficient to ensure engraftment in matched unrelated bone
marrow transplantation. Exp Hematol 29:362–370.
25. Giralt S, PF Thall, I Khouri, X Wang, I Braunschweig, C Ip-
politi, DF Claxton, M Donato, J Bruton, A Cohen, M Davis,
B Andersson, P Anderlini, J Gajewski, S Kornblau, M An-
dreef, D Przepiorka, NT Ueno, J Molldrem and R Champlin.
(2001). Melphalan and purine analog-containing preparative
regimens: reduced-intensity conditioning for patients with
hematologic malignancies undergoing allogeneic progenitor
cell transplantation. Blood 97:631–637.
26. Mohty M, C Faucher, N Vey, AM Stoppa, F Viret, I Chab-
bert, C Chabannon, R Bouabdallah, P Ladaique, L Collet,
C Zandotti, D Maraninchi and D Blaise. (2000). High rate
of secondary viral and bacterial infections in patients un-
dergoing allogeneic bone marrow mini-transplantation.
Bone Marrow Transplant 26:251–255.
27. Kottaridis PD, DW Milligan, R Chopra, R Chakraverty, S
Chakrabarti, S Robinson, K Peggs, DC Linch and S Mack-
innon. (2000). In vivo CAMPATH-1H prevents graft-ver-
sus-host disease following nonmyeloablative stem cell
transplantation. Blood 96:2419–2425.
28. Bornhausser M, C Thiede, U Platzbecker, J Freiberg-
Richter, A Helwig, R Plettig, C Röllig and G Ehninger.
(2000). Dose-reduced conditioning for allogeneic blood
stem cell transplantation: durable engraftment without an-
tithymocyte globulin. Bone Marrow Transplant
26:119–125.
29. Barrett AJ and R Childs. (2000). Non-myeloablative stem
cell transplants. Br J Haematol 111:6–17.
30. Lau FY, R Wong, CH Chui and G Cheng. (2001). Suc-
cessful engraftment in two adult patients with severe aplas-
tic anemia using nonmyeloablative conditioning followed
by unrelated hla-mismatched cord blood transplantation. J
Hematother Stem Cell Res 10:309–311.
31. Childs R, E Clave, N Contentin, D Jayasekara, N Hensel,
S Leitman, EJ Read, C Carter, E Bahceci, NS Young and
AJ Barrett. (1999). Engraftment kinetics after nonmye-
loablative allogeneic peripheral blood stem cell transplan-
tation: full donor T-cell chimerism precedes alloimmune
response. Blood 94:3234–3241.
32. Carella AM, S Giralt and S Slavin. (2000). Low intensity
regimens with allogeneic hematopoietic stem cell trans-
plantation as treatment of hematologic neoplasia. Haema-
tologica 85:304–313.
33. Storb R. (2001). Nonmyeloablative preparative regimens:
how relevant for acute myelogenous leukemia? Leukemia
15:662–663.
34. McSweeney PA, D Niederwieser, J Shizuru, BM Sand-
maier, A Molina, DG Maloney, TR Chauncey, T Gooley,
U Hegenbart, RA Nash, J Radich, JL Wagner, S Minor, FR
Appelbaum, WI Bensinger, E Bryan, ED Flowers, G
Georges, FC Grumet, HP Kiem, B Torok-Storb, C Yu, KG
Blume and R Storb. (2001). Hematopoietic cell transplan-
tation in older patients with hematologic malignancies: re-
placing high-dose cytotoxic therapy with graft-versus-tu-
mor effects. Blood 97:3390–3400.
35. Baron F, J Siquet, E Baudoux, N Schaaf-Lafontaine, JP
Hermanne, G Fillet and Y Beguin. (2002). Pre-emptive im-
munotherapy with CD8-depleted donor lymphocytes after
CD34-selected allogeneic peripheral blood stem cell trans-
plantation. Haematologica 87:78–88.
36. Przepiorka D, D Weisdorf, P Martin, HG Klingemann, P
Beatty, J Hows and ED Thomas. (1995). 1994 Consensus
Conference on Acute GVHD Grading. Bone Marrow
Transplant 15:825–828.
37. Margolis J and G Vogelsang. (2000). Chronic graft-versus-
host disease. J Hematother Stem Cell Ress 9:339–346.
38. Thiede C, M Bornhausser, U Oelschlägel, C Brendel, R
Leo, H Daxberger, B Mohr, M Florek, F Kroschinsky, G
Geissler, R Naumann, M Ritter, G Prange-Krex, T Lion, A
Neubauer and G Ehninger. (2001). Sequential monitoring
of chimerism and detection of minimal residual disease af-
ter allogeneic bone marrow transplantation (BSCT) using
multiplex PCR amplification of short tandem repeat mark-
ers. Leukemia 15:293–302.
39. Bearman SI, FR Appelbaum, CD Buckner, FB Petersen,
LD Fisher, RA Clift and ED Thomas. (1988). Regimen-re-
lated toxicity in patients undergoing bone marrow trans-
plantation. J Clin Oncol 6:1562–1568.
40. Martin P, S Rowley, C Anasetti, TR Chauncey, T Gooley,
E Petersdorf, JO Burik, M Flowers, R Storb, FR Appel-
baum, and J Hansen. (1999). A phase I-II clinical trial to
evaluate removal of CD4 cells and partial depletion of CD8
cells from donor marrow for HLA-mismatched unrelated
recipients. Blood 94:2192–2199.
41. Pelot MR, DA Pearson, K Swenson, G Zhao, J Sachs, YG
Yang and M Sykes. (1999). Lymphohematopoietic graft-
versus-host reactions can be induced without graft-versus-
host disease in murine mixed chimeras established with a
cyclophosphamide-based non-myeloablative conditioning
regimen. Biol Blood Marrow Transplant 5:133–143.
42. Kolb HJ, W Gunther, M Schumm, E Holler, W Wilmanns
and S Thierfelder. (1997). Adoptive immunotherapy in ca-
nine chimeras. Transplantation 63:430–436.
43. Barrett AJ, D Mavroudis, J Tisdale and E Read. (1998). T
cell-depleted bone marrow transplantation and delayed T
cell add-back to control acute GVHD and conserve a graft-
versus-leukemia effect. Bone Marrow Transplant 21:
543–551.
44. Michallet M, K Bilger, F Garban, M Attal, A Huyn, D
Blaise, N Milpied, P Moreau, P Bordigoni, M Kuentz, A
Sadoun, JY Cahan , G Socié, X Thomas, P Arnaud, N Raus,
V Lhéritier, A Pigneux and JM Boiron. (2001). Allogeneic
hematopoietic stem cell transplantation after nonmyeloab-
lative preparative regimens: impact of pretransplantation
and posttransplantation factors on outcome. J Clin Oncol
19:3340–3349.
45. Walter EA, PD Greenberg, MJ Gilbert, RJ Finch, KS
Watanabe, Thomas, ED and SR Riddell. (1995). Reconsti-
tution of cellular immunity against cytomegalovirus in re-
cipients of allogeneic bone marrow by transfer of T-cell
clones from the donor. N Engl J Med 333:1038–1044.
46. Rooney CM, CA Smith, CY Ng, SK Loftin, JW Sixbey, Y
Gan, DK Srivastava, LC Bowman, RA Krance, MK Bren-
ner and HE Heslop. (1998). Infusion of cytotoxic T cells
for the prevention and treatment of Epstein-Barr virus-in-
duced lymphoma in allogeneic transplant recipients
92:1549–1555.
NMSCT WITH CD8-DEPLETED OR CD34-SELECTED PBSC
313
47. Falkenburg JH, AR Wafelman, P Joosten, WM Smith,
CAM van Bergen, R Bongaerts, E Lurvink, M van der
Hoorn, P Kluck, JE Landegent, C Kluin-Nelemans, WE
Fibbe and R Willemze. (1999). Complete remission of ac-
celerated phase chronic myeloid leukemia by treatment
with leukemia reactive cytotoxic T lymphocytes. Blood
94:1201–1208.
48. Marijt WA and JH Falkenburg. (2001). Specific T cell ther-
apy in leukemia. J Hematother Stem Cell Res 10:493–500.
49. Warren E, P Greenberg and SR Riddell. (1998). Cytotoxic
T-lymphocyte-defined human minor histocompatibility
antigens with a restricted tissue distribution. Blood
91:2197–2207.
50. Mutis T, R Verdijk, E Schrama, B Esendam, A Brand and
E Goulmy. (1999). Feasibility of immunotherapy of re-
lapsed leukemia with ex vivo generated cytotoxic T lym-
phocytes specific for hematopoietic system-restricted mi-
nor histocompatibility antigens. Blood 93:2336–2341.
51. Osman Y, M Takahashi, Z Zheng, T Koike, K Toba, A Liu,
T Furukawa, S Aoki and Y Aizawa. (1999). Generation of
bcr-abl specific cytotoxic T-lymphocytes by using dendritic
cells pulsed with bcr-abl (b3a2) peptide: its applicability
for donor leukocyte transfusions in marrow grafted CML
patients. Leukemia 13:166–174.
52. Molldrem J, PP Lee, C Wang, K Felio, H Kantarjian, RE
Champlin and MM Davis. (2000). Evidence that specific
T lymphocytes may participate in the elimination of chronic
myelogenous leukemia. Nature Med 6:1018–1023.
53. Gao L, I Bellantuono, A Elsasser, SB Marley, MY Gor-
don, JM Goldman and HJ Stauss. (2000). Selective elimi-
nation of leukemic CD34(1) progenitor cells by cytotoxic
T lymphocytes specific for WT1. Blood 95:2198–2203.







Received October 12, 2001; accepted October 27, 2001.
BARON ET AL.
314
This article has been cited by:
1. P Frère, F Baron, C Bonnet, K Hafraoui, M Pereira, E Willems, G Fillet, Y Beguin. 2006. Infections
after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone
Marrow Transplantation 37:4, 411-418. [CrossRef]
2. Fr??d??ric Baron, Nicole Schaaf-Lafontaine, St??phanie Humblet-Baron, Nathalie Meuris, Emilie
Castermans, Etienne Baudoux, Pascale Fr??re, Vincent Bours, Georges Fillet, Yves Beguin. 2004. T-cell
reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood
stem-cell transplantation. Transplantation 76:12, 1705-1713. [CrossRef]
3. F. Baron , Y. Beguin . 2002. Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Journal
of Hematotherapy & Stem Cell Research 11:2, 243-263. [Abstract] [PDF] [PDF Plus]
